Tags

Type your tag names separated by a space and hit enter

A study of the role of DIO1 and DIO2 polymorphism in thyroid cancer and drug response to therapy in the Saudi population.
Saudi Pharm J 2019; 27(6):841-845SP

Abstract

Background

Deiodinases comprise a group of selenoproteins that regulate the bioavailability of active thyroid hormones (TH) in a time and tissue specific fashion. They increase the hormonal activity by metabolizing their inactive precursors to active forms or terminate their activity by deactivating active hormones. The role of the deiodinase (DIO) gene polymorphisms in thyroid cancer is not fully understood yet. This study evaluated the potential association of the DIO1 and DIO2 genes with differentiated thyroid cancer and differential thyroxine dose requirement in thyroidectomized patients in a Saudi cohort.

Methods

We selected four variants (one DIO1 and three DIO2) for the association studies using Taqman assays in 507 DTC patients undergoing treatment with thyroxin against 560 disease-free individual, all of Saudi Arab origin.

Results

None of the studied variants was linked to differentiated thyroid cancer. The rs1388378_G > T was initially linked to thyroxine dose requirement (p = 0.035) when all patients were considered together, but this association was lost when the patients were classified into either near suppressed (0.1 ≤ TSH < 0.5) or suppressed (TSH < 0.1) TSH group.

Discussion

Although the results suggest only a weak relationship with differentiated thyroid cancer, they strongly indicate that the DIO2 polymorphism influences the hormonal dose requirement in patients undergoing treatment with thyroxine. This probably points to a distinction in the way this gene influences disease as compared to therapy thereof.

Authors+Show Affiliations

Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Kingdom of Saudi Arabia, P.O. Box 2457, Riyadh 11451, Saudi Arabia.Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Kingdom of Saudi Arabia, P.O. Box 2457, Riyadh 11451, Saudi Arabia.Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Kingdom of Saudi Arabia, P.O. Box 2457, Riyadh 11451, Saudi Arabia.Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Kingdom of Saudi Arabia, P.O. Box 2457, Riyadh 11451, Saudi Arabia.Department of Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31516326

Citation

AlRasheed, Maha M., et al. "A Study of the Role of DIO1 and DIO2 Polymorphism in Thyroid Cancer and Drug Response to Therapy in the Saudi Population." Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society, vol. 27, no. 6, 2019, pp. 841-845.
AlRasheed MM, AlAnzi A, AlShalhoub R, et al. A study of the role of DIO1 and DIO2 polymorphism in thyroid cancer and drug response to therapy in the Saudi population. Saudi Pharm J. 2019;27(6):841-845.
AlRasheed, M. M., AlAnzi, A., AlShalhoub, R., Abanmy, N., & Bakheet, D. (2019). A study of the role of DIO1 and DIO2 polymorphism in thyroid cancer and drug response to therapy in the Saudi population. Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society, 27(6), pp. 841-845. doi:10.1016/j.jsps.2019.05.005.
AlRasheed MM, et al. A Study of the Role of DIO1 and DIO2 Polymorphism in Thyroid Cancer and Drug Response to Therapy in the Saudi Population. Saudi Pharm J. 2019;27(6):841-845. PubMed PMID: 31516326.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A study of the role of DIO1 and DIO2 polymorphism in thyroid cancer and drug response to therapy in the Saudi population. AU - AlRasheed,Maha M, AU - AlAnzi,Ashwaq, AU - AlShalhoub,Rawan, AU - Abanmy,Norah, AU - Bakheet,Dana, Y1 - 2019/05/21/ PY - 2019/02/11/received PY - 2019/05/20/accepted PY - 2019/9/14/entrez PY - 2019/9/14/pubmed PY - 2019/9/14/medline KW - D (1, 2), deiodinase (1,2) protein KW - DIO (1,2,3), deiodinase (1,2,3) gene KW - Deiodinase 1 KW - Deiodinase 2 thyroxine therapy KW - Differentiated thyroid cancer KW - FT4, free thyroxin KW - T3, triiodothyronine KW - T4, tetraiodothyronine KW - TH, thyroid hormone KW - TSHβ, thyroid-stimulating homorne-β KW - UDP, uridine phosphorylase KW - UGT1A, UDP glucuronosyltransferase family 1 member A KW - WSB-1, WB repeat and SOCs box-containing KW - rs1388378 SP - 841 EP - 845 JF - Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society JO - Saudi Pharm J VL - 27 IS - 6 N2 - Background: Deiodinases comprise a group of selenoproteins that regulate the bioavailability of active thyroid hormones (TH) in a time and tissue specific fashion. They increase the hormonal activity by metabolizing their inactive precursors to active forms or terminate their activity by deactivating active hormones. The role of the deiodinase (DIO) gene polymorphisms in thyroid cancer is not fully understood yet. This study evaluated the potential association of the DIO1 and DIO2 genes with differentiated thyroid cancer and differential thyroxine dose requirement in thyroidectomized patients in a Saudi cohort. Methods: We selected four variants (one DIO1 and three DIO2) for the association studies using Taqman assays in 507 DTC patients undergoing treatment with thyroxin against 560 disease-free individual, all of Saudi Arab origin. Results: None of the studied variants was linked to differentiated thyroid cancer. The rs1388378_G > T was initially linked to thyroxine dose requirement (p = 0.035) when all patients were considered together, but this association was lost when the patients were classified into either near suppressed (0.1 ≤ TSH < 0.5) or suppressed (TSH < 0.1) TSH group. Discussion: Although the results suggest only a weak relationship with differentiated thyroid cancer, they strongly indicate that the DIO2 polymorphism influences the hormonal dose requirement in patients undergoing treatment with thyroxine. This probably points to a distinction in the way this gene influences disease as compared to therapy thereof. SN - 1319-0164 UR - https://www.unboundmedicine.com/medline/citation/31516326/A_study_of_the_role_of_DIO1_and_DIO2_polymorphism_in_thyroid_cancer_and_drug_response_to_therapy_in_the_Saudi_population L2 - https://linkinghub.elsevier.com/retrieve/pii/S1319-0164(19)30076-3 DB - PRIME DP - Unbound Medicine ER -